Tracon Pharmaceuticals said today it has licensed two preclinical oncology candidates from Johnson & Johnson’s Janssen Pharmaceutica, which will retain rights to potentially reacquire the programs.
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results